JP2017528476A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017528476A5 JP2017528476A5 JP2017513774A JP2017513774A JP2017528476A5 JP 2017528476 A5 JP2017528476 A5 JP 2017528476A5 JP 2017513774 A JP2017513774 A JP 2017513774A JP 2017513774 A JP2017513774 A JP 2017513774A JP 2017528476 A5 JP2017528476 A5 JP 2017528476A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- seq
- nos
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010023082 activin A Proteins 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 230000000750 progressive effect Effects 0.000 claims 1
- 102100021886 Activin receptor type-2A Human genes 0.000 description 4
- 102100027647 Activin receptor type-2B Human genes 0.000 description 4
- 101000970954 Homo sapiens Activin receptor type-2A Proteins 0.000 description 4
- 101000937269 Homo sapiens Activin receptor type-2B Proteins 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 230000011664 signaling Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462049869P | 2014-09-12 | 2014-09-12 | |
| US62/049,869 | 2014-09-12 | ||
| US201562141775P | 2015-04-01 | 2015-04-01 | |
| US62/141,775 | 2015-04-01 | ||
| PCT/US2015/000100 WO2016039796A2 (en) | 2014-09-12 | 2015-09-14 | Treatment of fibrodysplasia ossificans progressiva |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017528476A JP2017528476A (ja) | 2017-09-28 |
| JP2017528476A5 true JP2017528476A5 (OSRAM) | 2018-10-04 |
| JP6560341B2 JP6560341B2 (ja) | 2019-08-14 |
Family
ID=54207748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017513774A Active JP6560341B2 (ja) | 2014-09-12 | 2015-09-14 | 進行性骨化性線維異形成症の治療 |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US20160075772A1 (OSRAM) |
| EP (2) | EP3604335A1 (OSRAM) |
| JP (1) | JP6560341B2 (OSRAM) |
| KR (1) | KR102564079B1 (OSRAM) |
| CN (1) | CN107106648B (OSRAM) |
| AU (1) | AU2015315829B2 (OSRAM) |
| CA (1) | CA2960950C (OSRAM) |
| CL (2) | CL2017000603A1 (OSRAM) |
| CY (1) | CY1122188T1 (OSRAM) |
| DK (1) | DK3191512T3 (OSRAM) |
| ES (1) | ES2739605T3 (OSRAM) |
| HR (1) | HRP20191929T1 (OSRAM) |
| HU (1) | HUE046558T2 (OSRAM) |
| IL (1) | IL251063B (OSRAM) |
| LT (1) | LT3191512T (OSRAM) |
| MA (1) | MA40621B1 (OSRAM) |
| ME (1) | ME03541B (OSRAM) |
| MX (1) | MX382026B (OSRAM) |
| MY (1) | MY179654A (OSRAM) |
| NZ (1) | NZ730773A (OSRAM) |
| PL (1) | PL3191512T3 (OSRAM) |
| PT (1) | PT3191512T (OSRAM) |
| RS (1) | RS59412B1 (OSRAM) |
| SG (2) | SG11201701913SA (OSRAM) |
| SI (1) | SI3191512T1 (OSRAM) |
| SM (1) | SMT201900584T1 (OSRAM) |
| TW (1) | TWI688402B (OSRAM) |
| WO (1) | WO2016039796A2 (OSRAM) |
| ZA (1) | ZA201702112B (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8871209B2 (en) | 2011-11-14 | 2014-10-28 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or Activin A |
| TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| US20160075772A1 (en) | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
| KR20170135967A (ko) | 2015-04-15 | 2017-12-08 | 리제너론 파마슈티칼스 인코포레이티드 | Gdf8 억제제를 사용하여 강도 및 기능을 증가시키는 방법 |
| RS61881B1 (sr) | 2015-04-22 | 2021-06-30 | Biogen Ma Inc | Novi hibridni actriib proteini zamke za ligand za lečenje bolesti gubljenja mišića |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| EP3415527B1 (de) | 2017-06-14 | 2025-12-10 | Kymab Ltd. | Verwendung der extrazellulären domäne des transferrinrezeptor 2 zur diagnostik und behandlung von primär und sekundär sklerosierenden erkrankungen |
| US11248044B2 (en) | 2018-03-01 | 2022-02-15 | Regeneron Pharmaceuticals, Inc. | Methods for altering body composition by administering a GDF8 inhibitor and an Activin A inhibitor |
| CN111836643A (zh) * | 2018-03-05 | 2020-10-27 | 学校法人埼玉医科大学 | 用于治疗或预防异位骨化的药物组合物 |
| JP7420730B2 (ja) | 2018-04-06 | 2024-01-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 代謝機能不全または低レプチン血症の治療に使用するためのレプチン受容体アゴニスト性抗体 |
| EP3806885A2 (en) | 2018-06-13 | 2021-04-21 | Kymab Limited | Antagonists and agonists of the transferrin receptor-2 for use in the treatment of diseases of the bone |
| AU2019284762A1 (en) | 2018-06-13 | 2020-11-19 | Regeneron Pharmaceuticals, Inc. | A rodent model of fibrodysplasia ossificans progressiva |
| JP2021533200A (ja) | 2018-08-02 | 2021-12-02 | ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. | 顔面・肩甲・上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
| EP3829645A4 (en) * | 2018-08-02 | 2022-05-18 | Dyne Therapeutics, Inc. | MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF PROGRESSIVE FIBRODYSPLASIA OSSIFIANS |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| EP3870613A4 (en) * | 2018-10-23 | 2022-08-03 | Keros Therapeutics, Inc. | ALK2 ANTIBODIES AND METHODS OF USE THEREOF |
| KR20210104744A (ko) * | 2018-12-18 | 2021-08-25 | 리제너론 파마슈티칼스 인코포레이티드 | 렙틴 수용체, gdf8 및 액티빈 a에 대한 길항제를 사용하여 체중 및 제지방 근육량을 향상시키기 위한 조성물 및 방법 |
| KR20220139886A (ko) * | 2020-01-08 | 2022-10-17 | 리제너론 파아마슈티컬스, 인크. | 진행성 골화성 섬유이형성증의 치료 |
| WO2021142260A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of acvr1 |
| MX2022016403A (es) * | 2020-06-18 | 2023-04-11 | Regeneron Pharma | Formulaciones de anticuerpo de activina a y métodos para utilizarlas. |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| JP2023548346A (ja) * | 2020-11-11 | 2023-11-16 | ハン，ハック | アクチビン／ｔｇｆ－ベータおよびｒａｎｋｌの二機能性アンタゴニストならびにその使用 |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| CA3228901A1 (en) * | 2021-09-03 | 2023-03-09 | Chris Xiangyang Lu | Anti-acvr2a antibodies and uses thereof |
| CN121127502A (zh) * | 2023-05-15 | 2025-12-12 | 宜明凯尔生物医药技术(上海)有限公司 | 用于治疗肺高压的重组融合蛋白 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US6018026A (en) | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
| US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| DE69230142T2 (de) | 1991-05-15 | 2000-03-09 | Cambridge Antibody Technology Ltd. | Verfahren zur herstellung von spezifischen bindungspaargliedern |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
| US5877218A (en) | 1994-01-10 | 1999-03-02 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| CA2361492A1 (en) | 1999-02-05 | 2000-08-10 | Samsung Electronics Co., Ltd. | Image texture retrieving method and apparatus thereof |
| WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
| DK1709081T3 (da) | 2004-01-16 | 2011-06-06 | Regeneron Pharma | Fusionspolypeptider, der kan aktivere receptorer |
| ES2551852T3 (es) | 2004-07-23 | 2015-11-24 | Acceleron Pharma Inc. | Polipéptidos del receptor ActRII |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| US8859752B2 (en) * | 2006-04-18 | 2014-10-14 | The Trustees Of The University Of Pennsylvania | SIRNA-based therapy of Fibrodyplasia Ossificans Progressiva (FOP) |
| WO2008030611A2 (en) * | 2006-09-05 | 2008-03-13 | Medarex, Inc. | Antibodies to bone morphogenic proteins and receptors therefor and methods for their use |
| CL2007002567A1 (es) * | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| TWI782836B (zh) | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| CN103877564A (zh) | 2007-09-18 | 2014-06-25 | 阿塞勒隆制药公司 | 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途 |
| JP5270913B2 (ja) | 2007-12-26 | 2013-08-21 | サンゴバン・ティーエム株式会社 | 高電気抵抗高ジルコニア鋳造耐火物 |
| EP2265603B1 (en) * | 2008-03-13 | 2014-05-07 | The General Hospital Corporation | Inhibitors of the bmp signaling pathway |
| WO2009137075A1 (en) | 2008-05-06 | 2009-11-12 | Acceleron Pharma Inc. | Anti-activin antibodies and uses for promoting bone growth |
| JP5941842B2 (ja) * | 2010-06-18 | 2016-06-29 | Ｌｓｉｐファンド運営合同会社 | 優性アレル発現抑制剤 |
| WO2013063536A1 (en) * | 2011-10-27 | 2013-05-02 | Acceleron Pharma, Inc. | Actriib binding agents and uses thereof |
| US8871209B2 (en) * | 2011-11-14 | 2014-10-28 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or Activin A |
| WO2014051109A1 (ja) | 2012-09-28 | 2014-04-03 | 協和発酵キリン株式会社 | 抗ヒトｂｍｐ９抗体および該抗体を有効成分とする異所性骨化疾患の治療剤 |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| JP6601687B2 (ja) * | 2014-03-31 | 2019-11-06 | 大日本住友製薬株式会社 | 進行性骨化性線維異形成症の予防剤及び治療剤 |
| US20160075772A1 (en) | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
| CN108271359B (zh) * | 2015-02-13 | 2021-11-09 | 索伦托药业有限公司 | 结合ctla4的抗体治疗剂 |
| CA2984249A1 (en) | 2015-04-29 | 2016-11-03 | Regeneron Pharmaceuticals, Inc. | Treatment of fibrodysplasia ossificans progressiva |
-
2015
- 2015-09-10 US US14/850,844 patent/US20160075772A1/en not_active Abandoned
- 2015-09-11 TW TW104130079A patent/TWI688402B/zh active
- 2015-09-14 LT LTEP15775835.0T patent/LT3191512T/lt unknown
- 2015-09-14 DK DK15775835.0T patent/DK3191512T3/da active
- 2015-09-14 SG SG11201701913SA patent/SG11201701913SA/en unknown
- 2015-09-14 RS RSP20191331 patent/RS59412B1/sr unknown
- 2015-09-14 CA CA2960950A patent/CA2960950C/en active Active
- 2015-09-14 ES ES15775835T patent/ES2739605T3/es active Active
- 2015-09-14 CN CN201580049029.1A patent/CN107106648B/zh active Active
- 2015-09-14 EP EP19177741.6A patent/EP3604335A1/en not_active Withdrawn
- 2015-09-14 IL IL251063A patent/IL251063B/en unknown
- 2015-09-14 SI SI201530852T patent/SI3191512T1/sl unknown
- 2015-09-14 MX MX2017003175A patent/MX382026B/es unknown
- 2015-09-14 JP JP2017513774A patent/JP6560341B2/ja active Active
- 2015-09-14 MY MYPI2017700819A patent/MY179654A/en unknown
- 2015-09-14 NZ NZ730773A patent/NZ730773A/en unknown
- 2015-09-14 AU AU2015315829A patent/AU2015315829B2/en active Active
- 2015-09-14 PT PT15775835T patent/PT3191512T/pt unknown
- 2015-09-14 MA MA40621A patent/MA40621B1/fr unknown
- 2015-09-14 SM SM20190584T patent/SMT201900584T1/it unknown
- 2015-09-14 HU HUE15775835A patent/HUE046558T2/hu unknown
- 2015-09-14 SG SG10201902175RA patent/SG10201902175RA/en unknown
- 2015-09-14 KR KR1020177009673A patent/KR102564079B1/ko active Active
- 2015-09-14 PL PL15775835T patent/PL3191512T3/pl unknown
- 2015-09-14 ME MEP-2019-279A patent/ME03541B/me unknown
- 2015-09-14 HR HRP20191929TT patent/HRP20191929T1/hr unknown
- 2015-09-14 WO PCT/US2015/000100 patent/WO2016039796A2/en not_active Ceased
- 2015-09-14 EP EP15775835.0A patent/EP3191512B1/en active Active
-
2017
- 2017-03-10 CL CL2017000603A patent/CL2017000603A1/es unknown
- 2017-03-27 ZA ZA2017/02112A patent/ZA201702112B/en unknown
- 2017-08-28 US US15/688,740 patent/US20180111983A1/en not_active Abandoned
-
2018
- 2018-10-17 CL CL2018002962A patent/CL2018002962A1/es unknown
-
2019
- 2019-09-17 CY CY20191100972T patent/CY1122188T1/el unknown
- 2019-09-23 US US16/579,126 patent/US11407822B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017528476A5 (OSRAM) | ||
| JP2020500538A5 (OSRAM) | ||
| JP2020508303A5 (OSRAM) | ||
| AR123305A2 (es) | Proteínas de unión a antígeno | |
| JP2018521638A5 (OSRAM) | ||
| MX2025004236A (es) | Anticuerpo anti proteina reguladora de se?ales alfa (sirpalfana) | |
| JP2019536806A5 (OSRAM) | ||
| IL259940B2 (en) | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists | |
| JP2019504032A5 (OSRAM) | ||
| JP2019522961A5 (OSRAM) | ||
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| JP2014205674A5 (OSRAM) | ||
| JP2013198490A5 (OSRAM) | ||
| JP2019528083A5 (OSRAM) | ||
| JP2010516229A5 (OSRAM) | ||
| RU2017104815A (ru) | Молекулы со специфичностью в отношении cd79 и cd22 | |
| RU2588467C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| JP2016063812A5 (OSRAM) | ||
| JP2017534577A5 (OSRAM) | ||
| PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
| JP2017533694A5 (OSRAM) | ||
| RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
| JP2016512551A5 (OSRAM) | ||
| JP2015522252A5 (OSRAM) | ||
| JP2015514094A5 (OSRAM) |